Myocarditis

CHICAGO — Patients and prescribers should be more aware of the potential for major adverse cardiac events after immune checkpoint inhibitor-based therapy, according to retrospective study results presented at ASCO Annual Meeting.

An analysis of nationwide data across four Nordic countries shows risk for myocarditis is rare but is highest among young males after a second COVID-19 vaccine dose.

The prevalence of acute myocarditis was low in hospitalized patients with COVID-19 during the first 14 months of the pandemic, researchers reported in Circulation.

Adults with a history of confirmed acute myocarditis did not experience recurrence or serious adverse events after COVID-19 vaccination, researchers reported.

The American College of Cardiology has published its expert decision pathway for the etiology, diagnosis and management of myocarditis and long COVID after COVID-19 infection.

Healio and Cardiology Today have created a list of the most-read cardiology news of January 2022.

Despite low absolute rates, researchers observed elevated odds of cardiac injury among male adolescents and young adults after messenger RNA-based COVID-19 vaccination in a large U.S. study, as well as a smaller study in Hong Kong.

Healio and Cardiology Today have aggregated a list of recent updates on the CV impact of COVID-19 infection and vaccination.

Healio and Cardiology Today have aggregated a list of the most-read news in cardiology of 2021.

There have been rare reports of myocarditis and pericarditis among people who have received a COVID-19 messenger RNA vaccine, with cases occurring especially among male adolescents and young adults, according to the CDC.